Susquehanna International Group, LLP Bluebird Bio, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.47 - $1.35 $98,324 - $282,420	-209,200 Reduced 61.89%	128,800 $66,000
Q2 2024 Aug 15, 2024	SELL	$0.85 - $1.26 $396,865 - $588,294	-466,900 Reduced 58.01%	338,000 $331,000
Q1 2024 May 07, 2024	SELL	$0.91 - $1.75 $326,872 - $628,600	-359,200 Reduced 30.86%	804,900 $1.03 Million
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $934,296 - $3.42 Million	707,800 Added 155.12%	1,164,100 $1.61 Million
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $421,290 - $564,975	139,500 Added 44.03%	456,300 $1.39 Million
Q2 2023 Aug 11, 2023	BUY	$2.79 - $5.03 $219,573 - $395,861	78,700 Added 33.05%	316,800 $1.04 Million
Q1 2023 May 16, 2023	BUY	$3.14 - $8.22 $469,430 - $1.23 Million	149,500 Added 168.74%	238,100 $757,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $290,808 - $427,896	-50,400 Reduced 36.26%	88,600 $613,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $73,125 - $144,105	19,500 Added 16.32%	139,000 $880,000

152

63.7M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $24.7M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.